Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

European Respiratory Journal

Volumn 35, Issue 3, 2010, Pages 479-495

  Scherpereel, A ^a   Astoul, P ^b   Baas, P ^c   Berghmans, T ^d   Clayson, H ^e   De Vuyst, P ^f   Dienemann, H ^g   Galateau Salle, F ^h   Hennequin, C ⁱ   Hillerdal, G ^j   Le Pechoux C ^k   Mutti, L ^l   Pairon, J C ^m   Stahel, R ⁿ   Van Houtte, P ^d   Van Meerbeeck, J ^o   Waller, D ^p   Weder, W ⁿ  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d JULES BORDET INSTITUTE   (Belgium)

^e Hospice of St Mary of Furness   (United Kingdom)

^f ERASME HOSPITAL   (Belgium)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h CAEN UNIVERSITY HOSPITAL   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k INSTITUT GUSTAVE ROUSSY   (France)

^l Laboratorio di Oncologia Clinica   (Italy)

^m INSERM   (France)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o GHENT UNIVERSITY HOSPITAL   (Belgium)

^p GLENFIELD HOSPITAL   (United Kingdom)

more..

Author keywords

Asbestos; Cancer; Guidelines; Mesothelioma; Pleura; Treatment

Indexed keywords

ANTIEMETIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CODEINE; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUCONAZOLE; GEFITINIB; GEMCITABINE; IMATINIB; INTERFERON; IRINOTECAN; MITOMYCIN C; MORPHINE; NAVELBINE; OXALIPLATIN; PEMETREXED; PHOLCODINE; PLATINUM DERIVATIVE; RALTITREXED; THALIDOMIDE; VINBLASTINE;

ANXIETY DISORDER; CANCER STAGING; CLINICAL TRIAL; COUGHING; DYSPNEA; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOW DRUG DOSE; MALIGNANT MESOTHELIOMA; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PLEURODESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THORACOSCOPY; THRUSH; TREATMENT CONTRAINDICATION; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PNEUMONECTOMY; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT;

EID: 77951177646     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00063109     Document Type: Review

References (100)

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408.
2. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92: 587-593.
3. Pass HI, Vogelzang N, Hahn S, et al. Malignant pleural mesothelioma. Curr Probl Cancer 2004; 28: 93-174.
4. Scherpereel A. Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med 2007; 101: 1265-1276. (Pubitemid 46671140)
5. Scherpereel A. [The experts' conference of the Societe de Pneumologie de Langue Francaise (SPLF) on malignant pleural mesothelioma (MPM): useful and necessary recommendations]. Rev Mal Respir 2006; 23: 11S5-11S6.
6. Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: Suppl. 2, ii43-ii44.
7. British Thoracic Society Standards of Care Committee, BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007; 62: Suppl. 2, ii1-ii19.
8. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College Of Chest Physicians task force. Chest 2006; 129: 174-181. (Pubitemid 43265259)
9. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960; 17: 260-271.
10. Goldberg M, Imbernon E, Rolland P, et al. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006; 63: 390-395. (Pubitemid 43828903)
11. Bourdes V, Boffetta P, Pisani P. Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis. Eur J Epidemiol 2000; 16: 411-417.
12. Maule MM, Magnani C, Dalmasso P, et al. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect 2007; 115: 1066-1071. (Pubitemid 47317074)
13. Iwatsubo Y, Pairon JC, Boutin C, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study. Am J Epidemiol 1998; 148: 133-142. (Pubitemid 128721148)
14. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34: 718-721.
15. Reid A, de Klerk N, Ambrosini G, et al. The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis. Occup Environ Med 2005; 62: 665-1659
16. Roushdy-Hammady I, Siegel J, Emri S, et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 2001; 357: 444-445. (Pubitemid 32156148)
17. Dogan AU, Baris YI, Dogan M, et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006; 66: 5063-5068. (Pubitemid 43844927)
18. Lin RT, Takahashi K, Karjalainen A, et al. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 2007; 369: 844-849. (Pubitemid 46365901)
19. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-1603.
20. Segura O, Burdorf A, Looman C. Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med 2003; 60: 50-55. (Pubitemid 36084228)
21. Montanaro F, Bray F, Gennaro V, et al. Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends. Cancer Causes Control 2003; 14: 791-803. (Pubitemid 37463893)
22. Pelucchi C, Malvezzi M, La Vecchia C, et al. The Mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004; 90: 1022-1024. (Pubitemid 38495822)
23. De Vuyst P, Karjalainen A, Dumortier P, et al. Guidelines for mineral fibre analyses in biological samples: report of the ERS Working Group. European Respiratory Society. Eur Respir J 1998; 11: 1416-1426. (Pubitemid 28298611)
24. Fasola G, Belvedere O, Aita M, et al. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial - an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002). Oncologist 2007; 12: 1215-1224. (Pubitemid 350106352)
25. Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007; 13: 339-443.
26. Park EK, Sandrini A, Yates DH, et al. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study. Am J Respir Crit Care Med 2008; 178: 832-837.
27. vanMeerbeeck JP, Hillerdal G. Screening for mesothelioma: more harm than good?Am J Respir Crit Care Med 2008; 178: 781-782.
28. Eibel R, Tuengerthal S, Schoenberg SO. The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma. Curr Opin Oncol 2003; 15: 131-138. (Pubitemid 36324219)
29. Wang ZJ, Reddy GP, Gotway MB, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 2004; 24: 105-119.
30. Francis RJ, Byrne MJ, van der Schaaf AA, et al. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007; 48: 1449-1458.
31. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005; 49: Suppl. 1, S27-S32.
32. Travis WD, Brambilla E, Muller-Hermelink HK, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC, 2004.
33. Wittekind Ch, Greene FL, Hutter RVP, et al., eds. UICC, International Union Against Cancer. TNM Atlas. Illustrated Guide to the TMN Classification of Malignant Tumours. 5th Edn, Berlin, Springer, 2004; pp. 169-176.
34. van Meerbeeck JP, Boyer M. Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 2005; 49: Suppl. 1, S123-S127.
35. Steele JP. Prognostic factors for mesothelioma. Hematol Oncol Clin North Am 2005; 19, 1041-1052: vi.
36. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988; 41: 525-530.
37. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
38. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 1564-1573. (Pubitemid 41434635)
39. Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 2007; 13: 2928-2935. (Pubitemid 46850705)
40. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 723-731.
41. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 145-152. (Pubitemid 28041592)
42. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889. (Pubitemid 46260274)
43. Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTCNCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007; 25: 5770-5776.
44. Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995; 107: 1454-1456.
45. Soysal O, Karaoglanoglu N, Demiracan S, et al. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur J Cardiothorac Surg 1997; 11: 210-213. (Pubitemid 27096656)
46. Halstead JC, Lim E, Venkateswaran RM, et al. Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma. Eur J Surg Oncol 2005; 31: 314-320. (Pubitemid 40361525)
47. Nakas A, Martin Ucar AE, Edwards JG, et al. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008; 33: 83-88.
48. Martin-Ucar AE, Edwards JG, Rengajaran A, et al. Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control. Eur J Cardiothorac Surg 2001; 20: 1117-1121.
49. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128: 138-146.
50. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788-795.
51. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-1202.
52. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108: 754-758.
53. O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22. (Pubitemid 47030694)
54. Muirhead R, O'Rourke N. Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource. Eur Respir J 2007; 30: 1021.
55. Chapman E, Berenstein E, Diéguez M, et al. Radiotherapy for malignant pleural mesothelioma. Cochrane Database Syst Rev 2006; 3: CD003880.
56. Baldini EH. External beam radiation therapy for the treatment of pleural mesothelioma. Thorac Surg Clin 2004; 14: 543-548.
57. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006; 65: 640-645.
58. Berghmans T, Brechot JM, Robinet G, et al. [Chemotherapy of malignant pleural mesothelioma.] Rev Mal Respir 2006; 23: 11S57-11S70.
59. Ellis P, Davies AM, Evans WK, et al. The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma. A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO). October 2005. www.cancercare.on.ca/pdf/pebc7-14-1f.pdf
60. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111-121.
61. Berghmans T LJ, Mascaux C, Meert AP, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis, 2003: 245-256.
62. Muers MF, Stephens RJ, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694.
63. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
64. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005; 16: 923-927.
65. Giaccone G, O'Brien ME, Byrne MJ, et al. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer 2002; 38: Suppl. 8, S19-S24.
66. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984; 54: 961-964.
67. Porta C, Zimatore M, Bonomi L, et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 2005; 48: 429-434.
68. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985; 69: 1431-1432.
69. Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer 2007; 109: 93-99.
70. Sorensen JB, SundstromS, Perell K, et al. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007; 2: 147-152.
71. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1698-1704.
72. DeVita VT Jr. The James Ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983; 51: 1209-1220.
73. Skipper HE, Schabel FM Jr, Wilcox WS. Experimental evaluation of potential anticancer agents. Xiii. on the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964; 35: 1-111.
74. Skipper HE. Laboratory models: some historical perspective. Cancer Treat Rep 1986; 70: 3-7.
75. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006; 17: 270-275.
76. Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4: 97-101.
77. Stebbing J, Powles T, McPherson K, et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63: 94-97.
78. Baas P, Boogerd W, Dalesio O, et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 2005; 48: 291-296.
79. Karrison TKH, Gandara DR, Lu C, et al. Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM). J Clin Oncol 2007; 25: Suppl. 20, 18S.
80. Govindan R, Kratzke RA, Herndon JE 2nd, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 2005; 11: 2300-2304.
81. Mathy A, Baas P, Dalesio O, et al. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 2005; 50: 83-86.
82. Millward MPF, Byrne M, Powell A, et al. Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22: 228.
83. Villano JL, Hussain AN, Stadler WM, et al. A phase II trial of imatinib mesylate in patients with malignant mesothelioma. Proc Am Soc Clin Oncol 2004; 22: Suppl. 15, 14s.
84. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007; 25: 2406-2413.
85. van Klaveren RJ, Aerts JG, de Bruin H, et al. Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 2004; 43: 63-69.
86. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.
87. Nowak AK. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 2005; 49: Suppl. 1, S37-S40.
88. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
89. Hollen PJ, Gralla RJ, Liepa AM, et al. Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso. Support Care Cancer 2006; 14: 11-21.
90. Senan S. Indications and limitations of radiotherapy in malignant pleural mesothelioma. Curr Opin Oncol 2003; 15: 144-147.
91. Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 1991; 20: 433-438.
92. Steele JP, Klabatsa A, Fennell DA, et al. Prognostic factors in mesothelioma. Lung Cancer 2005; 49: Suppl. 1, S49-S52.
93. Krug LMK, Pass H, Rusch VW, et al. A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2007; 25: Suppl. 20, 18S.
94. Van Schil P, Hasan B, Maat A, et al. EORTC 08031. The 9th international conference of the International Mesothelioma Interest Group. Amsterdam, The Netherlands, 2008: p. 174.
95. Monneuse O, Beaujard AC, Guibert B, et al. Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Br J Cancer 2003; 88: 1839-1843.
96. van Ruth S, Baas P, Haas RL, et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003; 10: 176-182.
97. Xia H, Karasawa K, Hanyu N, et al. Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma. Int J Hyperthermia 2006; 22: 613-621.
98. Nowak AK, Stockler MR, Byrne MJ. Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 2004; 22: 3172-3180.
99. Ahmedzai S, Clayson H. Palliative care for mesothelioma. In: O'Byrne K, Rusch V, eds. Malignant Pleural Mesothelioma. Oxford, Oxford University Press, 2006: pp. 412-418.
100. Corner J, Plant H, A'Hern R, et al. Non-pharmacological intervention for breathlessness in lung cancer. Palliat Med 1996; 10: 299-305.